Compare Stocks

5 / 10
Try these comparisons:

Stock Comparison

ZJYL vs MPWR vs NVCR vs LFUS vs GKOS

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
ZJYL
Jin Medical International Ltd.

Medical - Instruments & Supplies

HealthcareNASDAQ • CN
Market Cap$344M
5Y Perf.-70.5%
MPWR
Monolithic Power Systems, Inc.

Semiconductors

TechnologyNASDAQ • US
Market Cap$77.41B
5Y Perf.+214.9%
NVCR
NovoCure Limited

Medical - Instruments & Supplies

HealthcareNASDAQ • JE
Market Cap$1.92B
5Y Perf.-72.0%
LFUS
Littelfuse, Inc.

Hardware, Equipment & Parts

TechnologyNASDAQ • US
Market Cap$11.11B
5Y Perf.+64.7%
GKOS
Glaukos Corporation

Medical - Devices

HealthcareNYSE • US
Market Cap$7.85B
5Y Perf.+167.8%

ZJYL vs MPWR vs NVCR vs LFUS vs GKOS — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
ZJYL logoZJYL
MPWR logoMPWR
NVCR logoNVCR
LFUS logoLFUS
GKOS logoGKOS
IndustryMedical - Instruments & SuppliesSemiconductorsMedical - Instruments & SuppliesHardware, Equipment & PartsMedical - Devices
Market Cap$344M$77.41B$1.92B$11.11B$7.85B
Revenue (TTM)$43M$2.79B$674M$2.49B$551M
Net Income (TTM)$5M$616M$-173M$-40M$-189M
Gross Margin35.8%55.2%75.2%38.3%78.1%
Operating Margin10.0%26.1%-27.2%2.8%-15.6%
Forward P/E93.6x73.1x33.8x
Total Debt$12M$24M$290M$946M$140M
Cash & Equiv.$8M$1.10B$103M$563M$91M

ZJYL vs MPWR vs NVCR vs LFUS vs GKOSLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

ZJYL
MPWR
NVCR
LFUS
GKOS
StockMar 23May 26Return
Jin Medical Interna… (ZJYL)10029.5-70.5%
Monolithic Power Sy… (MPWR)100314.9+214.9%
NovoCure Limited (NVCR)10028.0-72.0%
Littelfuse, Inc. (LFUS)100164.7+64.7%
Glaukos Corporation (GKOS)100267.8+167.8%

Price return only. Dividends and distributions are not included.

Quick Verdict: ZJYL vs MPWR vs NVCR vs LFUS vs GKOS

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: MPWR leads in 3 of 7 categories (5-stock set), making it the strongest pick for profitability and margin quality and recent price momentum and sentiment. Littelfuse, Inc. is the stronger pick specifically for valuation and capital efficiency and dividend income and shareholder returns. GKOS also leads in specific categories worth noting. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
ZJYL
Jin Medical International Ltd.
The Healthcare Pick

ZJYL lags the leaders in this set but could rank higher in a more targeted comparison.

Best for: healthcare exposure
MPWR
Monolithic Power Systems, Inc.
The Long-Run Compounder

MPWR carries the broadest edge in this set and is the clearest fit for long-term compounding and valuation efficiency.

  • 24.9% 10Y total return vs GKOS's 457.1%
  • PEG 2.48 vs ZJYL's 4.48
  • 22.1% margin vs GKOS's -34.3%
  • +148.6% vs ZJYL's -86.4%
Best for: long-term compounding and valuation efficiency
NVCR
NovoCure Limited
The Healthcare Pick

Among these 5 stocks, NVCR doesn't own a clear edge in any measured category.

Best for: healthcare exposure
LFUS
Littelfuse, Inc.
The Income Pick

LFUS is the #2 pick in this set and the best alternative if income & stability and defensive is your priority.

  • Dividend streak 16 yrs, beta 1.76, yield 0.7%
  • Beta 1.76, yield 0.7%, current ratio 2.69x
  • Better valuation composite
  • 0.7% yield, 16-year raise streak, vs MPWR's 0.4%, (3 stocks pay no dividend)
Best for: income & stability and defensive
GKOS
Glaukos Corporation
The Growth Play

GKOS ranks third and is worth considering specifically for growth exposure and sleep-well-at-night.

  • Rev growth 32.3%, EPS growth -18.4%, 3Y rev CAGR 21.5%
  • Lower volatility, beta 1.20, Low D/E 21.3%, current ratio 4.69x
  • 32.3% revenue growth vs NVCR's 8.3%
  • Beta 1.20 vs MPWR's 2.28
Best for: growth exposure and sleep-well-at-night
See the full category breakdown
CategoryWinnerWhy
GrowthGKOS logoGKOS32.3% revenue growth vs NVCR's 8.3%
ValueLFUS logoLFUSBetter valuation composite
Quality / MarginsMPWR logoMPWR22.1% margin vs GKOS's -34.3%
Stability / SafetyGKOS logoGKOSBeta 1.20 vs MPWR's 2.28
DividendsLFUS logoLFUS0.7% yield, 16-year raise streak, vs MPWR's 0.4%, (3 stocks pay no dividend)
Momentum (1Y)MPWR logoMPWR+148.6% vs ZJYL's -86.4%
Efficiency (ROA)MPWR logoMPWR15.2% ROA vs GKOS's -20.1%, ROIC 22.2% vs -9.2%

ZJYL vs MPWR vs NVCR vs LFUS vs GKOS — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

ZJYLJin Medical International Ltd.

Segment breakdown not available.

MPWRMonolithic Power Systems, Inc.
FY 2023
DC To DC Products
94.4%$1.7B
Lighting Control Products
5.6%$102M
NVCRNovoCure Limited

Segment breakdown not available.

LFUSLittelfuse, Inc.
FY 2025
Electronics Segment
56.4%$1.3B
Transportation Segment
28.3%$676M
Industrial Products
15.3%$364M
GKOSGlaukos Corporation
FY 2019
Glaucoma
97.5%$231M
Corneal Health
2.5%$6M

ZJYL vs MPWR vs NVCR vs LFUS vs GKOS — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLMPWRLAGGINGGKOS

Income & Cash Flow (Last 12 Months)

MPWR leads this category, winning 3 of 6 comparable metrics.

MPWR is the larger business by revenue, generating $2.8B annually — 65.0x ZJYL's $43M. MPWR is the more profitable business, keeping 22.1% of every revenue dollar as net income compared to GKOS's -34.3%. On growth, GKOS holds the edge at +41.2% YoY revenue growth, suggesting stronger near-term business momentum.

MetricZJYL logoZJYLJin Medical Inter…MPWR logoMPWRMonolithic Power …NVCR logoNVCRNovoCure LimitedLFUS logoLFUSLittelfuse, Inc.GKOS logoGKOSGlaukos Corporati…
RevenueTrailing 12 months$43M$2.8B$674M$2.5B$551M
EBITDAEarnings before interest/tax$5M$781M-$165M$227M-$40M
Net IncomeAfter-tax profit$5M$616M-$173M-$40M-$189M
Free Cash FlowCash after capex-$581,373$664M-$48M$390M-$18M
Gross MarginGross profit ÷ Revenue+35.8%+55.2%+75.2%+38.3%+78.1%
Operating MarginEBIT ÷ Revenue+10.0%+26.1%-27.2%+2.8%-15.6%
Net MarginNet income ÷ Revenue+10.9%+22.1%-25.7%-1.6%-34.3%
FCF MarginFCF ÷ Revenue-1.4%+23.8%-7.1%+15.7%-3.4%
Rev. Growth (YoY)Latest quarter vs prior year-6.4%+20.8%+12.3%+18.5%+41.2%
EPS Growth (YoY)Latest quarter vs prior year-105.3%-88.4%-100.0%+69.1%-6.3%
MPWR leads this category, winning 3 of 6 comparable metrics.

Valuation Metrics

LFUS leads this category, winning 5 of 7 comparable metrics.

At 93.6x trailing earnings, ZJYL trades at a 24% valuation discount to MPWR's 123.6x P/E. Adjusting for growth (PEG ratio), MPWR offers better value at 4.19x vs ZJYL's 4.48x — a lower PEG means you pay less per unit of expected earnings growth.

MetricZJYL logoZJYLJin Medical Inter…MPWR logoMPWRMonolithic Power …NVCR logoNVCRNovoCure LimitedLFUS logoLFUSLittelfuse, Inc.GKOS logoGKOSGlaukos Corporati…
Market CapShares × price$344M$77.4B$1.9B$11.1B$7.9B
Enterprise ValueMkt cap + debt − cash$348M$76.3B$2.1B$11.5B$7.9B
Trailing P/EPrice ÷ TTM EPS93.62x123.60x-13.80x-152.27x-40.90x
Forward P/EPrice ÷ next-FY EPS est.73.12x33.79x
PEG RatioP/E ÷ EPS growth rate4.48x4.19x
EV / EBITDAEnterprise value multiple87.30x97.90x83.21x
Price / SalesMarket cap ÷ Revenue14.65x27.74x2.92x4.66x15.47x
Price / BookPrice ÷ Book value/share12.06x21.56x5.51x4.53x11.69x
Price / FCFMarket cap ÷ FCF116.20x30.35x
LFUS leads this category, winning 5 of 7 comparable metrics.

Profitability & Efficiency

MPWR leads this category, winning 7 of 9 comparable metrics.

MPWR delivers a 17.9% return on equity — every $100 of shareholder capital generates $18 in annual profit, vs $-51 for NVCR. MPWR carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to NVCR's 0.85x. On the Piotroski fundamental quality scale (0–9), MPWR scores 6/9 vs ZJYL's 2/9, reflecting solid financial health.

MetricZJYL logoZJYLJin Medical Inter…MPWR logoMPWRMonolithic Power …NVCR logoNVCRNovoCure LimitedLFUS logoLFUSLittelfuse, Inc.GKOS logoGKOSGlaukos Corporati…
ROE (TTM)Return on equity+16.9%+17.9%-50.8%-1.6%-26.5%
ROA (TTM)Return on assets+9.7%+15.2%-16.5%-1.0%-20.1%
ROICReturn on invested capital+10.3%+22.2%-16.4%+1.0%-9.2%
ROCEReturn on capital employed+13.8%+20.4%-28.9%+1.1%-10.3%
Piotroski ScoreFundamental quality 0–926553
Debt / EquityFinancial leverage0.41x0.01x0.85x0.39x0.21x
Net DebtTotal debt minus cash$3M-$1.1B$187M$383M$49M
Cash & Equiv.Liquid assets$8M$1.1B$103M$563M$91M
Total DebtShort + long-term debt$12M$24M$290M$946M$140M
Interest CoverageEBIT ÷ Interest expense20.63x-96.80x-0.93x-18.69x
MPWR leads this category, winning 7 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

MPWR leads this category, winning 6 of 6 comparable metrics.

A $10,000 investment in MPWR five years ago would be worth $46,617 today (with dividends reinvested), compared to $875 for NVCR. Over the past 12 months, MPWR leads with a +148.6% total return vs ZJYL's -86.4%. The 3-year compound annual growth rate (CAGR) favors MPWR at 56.1% vs NVCR's -37.6% — a key indicator of consistent wealth creation.

MetricZJYL logoZJYLJin Medical Inter…MPWR logoMPWRMonolithic Power …NVCR logoNVCRNovoCure LimitedLFUS logoLFUSLittelfuse, Inc.GKOS logoGKOSGlaukos Corporati…
YTD ReturnYear-to-date-51.1%+68.5%+28.3%+68.5%+21.2%
1-Year ReturnPast 12 months-86.4%+148.6%+1.1%+132.6%+52.0%
3-Year ReturnCumulative with dividends-60.7%+280.3%-75.7%+73.3%+128.7%
5-Year ReturnCumulative with dividends-72.3%+366.2%-91.3%+71.8%+61.5%
10-Year ReturnCumulative with dividends-72.3%+2494.7%+30.3%+317.6%+457.1%
CAGR (3Y)Annualised 3-year return-26.8%+56.1%-37.6%+20.1%+31.7%
MPWR leads this category, winning 6 of 6 comparable metrics.

Risk & Volatility

Evenly matched — MPWR and GKOS each lead in 1 of 2 comparable metrics.

GKOS is the less volatile stock with a 1.20 beta — it tends to amplify market swings less than MPWR's 2.28 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. MPWR currently trades 94.8% from its 52-week high vs ZJYL's 12.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricZJYL logoZJYLJin Medical Inter…MPWR logoMPWRMonolithic Power …NVCR logoNVCRNovoCure LimitedLFUS logoLFUSLittelfuse, Inc.GKOS logoGKOSGlaukos Corporati…
Beta (5Y)Sensitivity to S&P 5001.57x2.28x2.20x1.76x1.20x
52-Week HighHighest price in past year$18.00$1662.00$20.06$475.00$146.75
52-Week LowLowest price in past year$0.12$613.00$9.82$188.08$73.16
% of 52W HighCurrent price vs 52-week peak+12.2%+94.8%+83.9%+93.0%+91.4%
RSI (14)Momentum oscillator 0–10053.771.069.876.263.0
Avg Volume (50D)Average daily shares traded22K577K1.5M265K678K
Evenly matched — MPWR and GKOS each lead in 1 of 2 comparable metrics.

Analyst Outlook

LFUS leads this category, winning 2 of 2 comparable metrics.

Analyst consensus: MPWR as "Buy", NVCR as "Buy", LFUS as "Buy", GKOS as "Buy". Consensus price targets imply 99.0% upside for NVCR (target: $34) vs -9.4% for LFUS (target: $400). For income investors, LFUS offers the higher dividend yield at 0.65% vs MPWR's 0.37%.

MetricZJYL logoZJYLJin Medical Inter…MPWR logoMPWRMonolithic Power …NVCR logoNVCRNovoCure LimitedLFUS logoLFUSLittelfuse, Inc.GKOS logoGKOSGlaukos Corporati…
Analyst RatingConsensus buy/hold/sellBuyBuyBuyBuy
Price TargetConsensus 12-month target$1615.00$33.50$400.00$146.67
# AnalystsCovering analysts25151124
Dividend YieldAnnual dividend ÷ price+0.4%+0.7%
Dividend StreakConsecutive years of raises816
Dividend / ShareAnnual DPS$5.90$2.89
Buyback YieldShare repurchases ÷ mkt cap0.0%+0.0%0.0%+0.2%0.0%
LFUS leads this category, winning 2 of 2 comparable metrics.
Key Takeaway

MPWR leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). LFUS leads in 2 (Valuation Metrics, Analyst Outlook). 1 tied.

Best OverallMonolithic Power Systems, I… (MPWR)Leads 3 of 6 categories
Loading custom metrics...

ZJYL vs MPWR vs NVCR vs LFUS vs GKOS: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is ZJYL or MPWR or NVCR or LFUS or GKOS a better buy right now?

For growth investors, Glaukos Corporation (GKOS) is the stronger pick with 32.

3% revenue growth year-over-year, versus 8. 3% for NovoCure Limited (NVCR). Jin Medical International Ltd. (ZJYL) offers the better valuation at 93. 6x trailing P/E, making it the more compelling value choice. Analysts rate Monolithic Power Systems, Inc. (MPWR) a "Buy" — based on 25 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — ZJYL or MPWR or NVCR or LFUS or GKOS?

On trailing P/E, Jin Medical International Ltd.

(ZJYL) is the cheapest at 93. 6x versus Monolithic Power Systems, Inc. at 123. 6x. On forward P/E, Littelfuse, Inc. is actually cheaper at 33. 8x — notably different from the trailing picture, reflecting expected earnings growth.

03

Which is the better long-term investment — ZJYL or MPWR or NVCR or LFUS or GKOS?

Over the past 5 years, Monolithic Power Systems, Inc.

(MPWR) delivered a total return of +366. 2%, compared to -91. 3% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: MPWR returned +24. 9% versus ZJYL's -72. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — ZJYL or MPWR or NVCR or LFUS or GKOS?

By beta (market sensitivity over 5 years), Glaukos Corporation (GKOS) is the lower-risk stock at 1.

20β versus Monolithic Power Systems, Inc. 's 2. 28β — meaning MPWR is approximately 90% more volatile than GKOS relative to the S&P 500. On balance sheet safety, Monolithic Power Systems, Inc. (MPWR) carries a lower debt/equity ratio of 1% versus 85% for NovoCure Limited — giving it more financial flexibility in a downturn.

05

Which is growing faster — ZJYL or MPWR or NVCR or LFUS or GKOS?

By revenue growth (latest reported year), Glaukos Corporation (GKOS) is pulling ahead at 32.

3% versus 8. 3% for NovoCure Limited (NVCR). On earnings-per-share growth, the picture is similar: NovoCure Limited grew EPS 21. 8% year-over-year, compared to -172. 5% for Littelfuse, Inc.. Over a 3-year CAGR, GKOS leads at 21. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — ZJYL or MPWR or NVCR or LFUS or GKOS?

Monolithic Power Systems, Inc.

(MPWR) is the more profitable company, earning 22. 1% net margin versus -37. 0% for Glaukos Corporation — meaning it keeps 22. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MPWR leads at 26. 1% versus -23. 5% for NVCR. At the gross margin level — before operating expenses — GKOS leads at 77. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is ZJYL or MPWR or NVCR or LFUS or GKOS more undervalued right now?

On forward earnings alone, Littelfuse, Inc.

(LFUS) trades at 33. 8x forward P/E versus 73. 1x for Monolithic Power Systems, Inc. — 39. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NVCR: 99. 0% to $33. 50.

08

Which pays a better dividend — ZJYL or MPWR or NVCR or LFUS or GKOS?

In this comparison, LFUS (0.

7% yield), MPWR (0. 4% yield) pay a dividend. ZJYL, NVCR, GKOS do not pay a meaningful dividend and should not be held primarily for income.

09

Is ZJYL or MPWR or NVCR or LFUS or GKOS better for a retirement portfolio?

For long-horizon retirement investors, Glaukos Corporation (GKOS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.

20), +457. 1% 10Y return). Monolithic Power Systems, Inc. (MPWR) carries a higher beta of 2. 28 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (GKOS: +457. 1%, MPWR: +24. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between ZJYL and MPWR and NVCR and LFUS and GKOS?

These companies operate in different sectors (ZJYL (Healthcare) and MPWR (Technology) and NVCR (Healthcare) and LFUS (Technology) and GKOS (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: ZJYL is a small-cap high-growth stock; MPWR is a mid-cap high-growth stock; NVCR is a small-cap quality compounder stock; LFUS is a mid-cap quality compounder stock; GKOS is a small-cap high-growth stock. LFUS pays a dividend while ZJYL, MPWR, NVCR, GKOS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

ZJYL

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Net Margin > 6%
Run This Screen
Stocks Like

MPWR

High-Growth Quality Leader

  • Sector: Technology
  • Market Cap > $100B
  • Revenue Growth > 10%
  • Net Margin > 13%
Run This Screen
Stocks Like

NVCR

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 6%
  • Gross Margin > 45%
Run This Screen
Stocks Like

LFUS

High-Growth Disruptor

  • Sector: Technology
  • Market Cap > $100B
  • Revenue Growth > 9%
  • Gross Margin > 22%
Run This Screen
Stocks Like

GKOS

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 20%
  • Gross Margin > 46%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform ZJYL and MPWR and NVCR and LFUS and GKOS on the metrics below

Revenue Growth>
%
(ZJYL: -6.4% · MPWR: 20.8%)
Net Margin>
%
(ZJYL: 10.9% · MPWR: 22.1%)
P/E Ratio<
x
(ZJYL: 93.6x · MPWR: 123.6x)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.